Editing Exelixis (section)

=== Pricing ===

==== Cabometyx (cabozantinib) ====
In 2023, the Institute for Clinical and Economic Review (ICER) identified Cabometyx (cabozantinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Cabometyx's wholesale acquisition cost rose by 7.5%, leading to an additional $86 million in costs to U.S. payers.<ref>{{Cite web |title=Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US |url=https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/?mkt_tok=NjM4LVBYUi0zMTgAAAGYMxe5Fv3mzhJbiVnr0V4g2FUAcS3PgZOZSYRvQcW3_VFPXIet0TCD7bWAyVVeW2Q62e3AynO8rDpP8sIoIbs_qux8kQcMBBD4cDSe3Q |access-date=2025-02-06 |website=ICER |language=en-US}}</ref>{{Portal|Companies}}
{{Commons category}}